Best FMCG Stocks In India 2024

Date:

Share post:

Hindustan Unilever Ltd

Market Cap  ₹ 606,101 Cr.

Debt  ₹ 1,043 Cr.

ROE  18.4 %

Sales growth  13.2 %

EPS  ₹ 39.0

Industry PE  62.3

Stock P/E  66.0

ROCE  24.4 %

Promoter holding  61.9 %

Pledged percentage  0.00 %

PEG Ratio  4.22

Net profit  ₹ 9,183 Cr.

Return on Equity:

10 Years: 45%

5 Years: 36%

3 Years: 28%

Last Year: 18%

Compounded Profit Growth:

10 Years: 13%

5 Years: 16%

3 Years: 13%

TTM: 11%

Compounded Sales Growth

10 Years: 8%

5 Years: 10%

3 Years: 10%

TTM: 13%

PROS:

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.4%
  • Company has been maintaining a healthy dividend payout of 96.4%

CONS:

  • Stock is trading at 12.4 times its book value
  • The company has delivered a poor sales growth of 9.60% over the past five years.
  • Promoter holding has decreased over last 3 years: -5.28%

Procter & Gamble Hygiene and Health Care Ltd

Market Cap  ₹ 45,860 Cr.

Debt  ₹ 5.10 Cr.

ROE  79.3 %

Sales growth  9.14 %

EPS  ₹ 177

Industry PE  62.3

Stock P/E  79.6

ROCE  110 %

Promoter holding  70.6 %

Net profit  ₹ 576 Cr.

PEG Ratio  14.3

Pledged percentage  0.00 %

Return on Equity:

10 Years: 44%

5 Years: 58%

3 Years: 62%

Last Year: 79%

Compounded Profit Growth:

10 Years: 12%

5 Years: 6%

3 Years: 11%

TTM: -12%

Compounded Sales Growth:

10 Years: 12%

5 Years: 11%

3 Years: 10%

TTM: 9%

PROS:

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 61.7%
  • Company has been maintaining a healthy dividend payout of 109%

CONS:

  • Stock is trading at 62.0 times its book value
  • The company has delivered a poor sales growth of 11.0% over the past five years.

 

Colgate-Palmolive (India) Ltd

Market Cap  ₹ 44,494 Cr.

Debt  ₹ 83.0 Cr.

ROE  74.4 %

Sales growth  3.30 %

EPS  ₹ 38.8

Industry PE  62.3

Stock P/E  42.0

ROCE  92.0 %

Promoter holding  51.0 %

Net profit  ₹ 1,055 Cr.

PEG Ratio  3.15

Pledged percentage  0.00 %

Return on Equity:

10 Years: 65%

5 Years: 60%

3 Years: 67%

Last Year: 74%

Compounded Profit Growth:

10 Years: 9%

5 Years: 13%

3 Years: 13%

TTM: -1%

Compounded Sales Growth:

10 Years: 7%

5 Years: 5%

3 Years: 5%

TTM: 3%

PROS:

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 67.4%
  • Company has been maintaining a healthy dividend payout of 98.0%

CONS:

  1. Stock is trading at 25.8 times its book value
  2. The company has delivered a poor sales growth of 5.07% over the past five years.

 

Related articles

Dr. Reddy’s Laboratories: Strong Growth, Rising Capex, But Is the Market Missing the Story?

🔬 Dr. Reddy’s Laboratories Ltd is showing all the right signs of aggressive expansion. Despite a decline in EBITDA...

MTAR Technologies: Rising Costs, Falling Profits, and Promoter Exit – Time to Reassess?

MTAR Technologies har quarter naye bade targets announce karti hai – ₹700 Cr+ revenue, 28% EBITDA margin, aur...

HUL: Sleeping Giant Ready to Break Out?

📈 Equity Research Update: Hindustan Unilever Ltd (HUL) Over the past 2–3 years, HUL’s stock has been consolidating in...

Pharma Sector Financial Overview

📊 Pharma Sector Financial Overview: Key Insights from the Latest Report 💊 🔹 Fixed Assets & Borrowings – How...
WhatsApp chat